BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 105,000 | $7,147,350 | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 11,840 | $806 | 0.00% |
| Avalon Trust Co | 596 | $40,570 | 0.00% |
| Rockefeller Capital Management L.P. | 15,233 | $1,036,947 | 0.00% |
| Evercore Wealth Management, LLC | 3,468 | $236,066 | 0.00% |
| Private Advisor Group, LLC | 6,931 | $471,809 | 0.00% |
| Red Tortoise LLC | 88 | $5,990 | 0.00% |
| STIFEL FINANCIAL CORP | 37,665 | $2,563,864 | 0.00% |
| Parallel Advisors, LLC | 1,843 | $125,453 | 0.00% |
| 1832 Asset Management L.P. | 46,200 | $3,144,834 | 0.00% |
| Mariner, LLC | 20,152 | $1,371,715 | 0.00% |
| AVIVA PLC | 14,087 | $958,902 | 0.00% |
| PFS Partners, LLC | 66 | $4,498 | 0.00% |
| B. Metzler seel. Sohn & Co. AG | 3,785 | $257,645 | 0.00% |
| AdvisorNet Financial, Inc | 713 | $48,534 | 0.00% |
| M&T BANK CORP | 12,989 | $884,539 | 0.00% |
| Capital World Investors | 272,339 | $18,538,116 | 0.00% |
| Desjardins Global Asset Management Inc. | 481 | $32,742 | 0.00% |
| Tradition Wealth Management, LLC | 424 | $29 | 0.00% |
| NATIONAL BANK OF CANADA /FI/ | 33,630 | $2,258,254 | 0.00% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.